The emergence of antibiotic-resistant bacteria has threatened our health worldwide. There is an urgent need for novel antibiotics. Previously, we identified a novel 37-mer antimicrobial peptide (AMP), HBcARD, with broad spectrum antimicrobial activity. Here, we improved the efficacy of HBcARD, by re-engineering the peptide, including the addition of a new cysteine to its C-terminus (CTC). The new 28-mer derivative, D-150-177C, contains all D-form arginines, in addition to a C-terminal cycteine. This peptide can kill antibiotic-resistant clinical isolates of Gram-negative bacteria, and is more potent than the parental HBcARD peptide in a mouse sepsis model. In another lung infection mouse model, D-150-177C showed protection efficacy against colistinresistant Acinetobacter baumannii. Unlike colistin, we observed no acute toxicity of D-150-177C in vivo. Interestingly, we found that CTC modification could enhance the antibacterial activity of several other AMPs, such as buforinII and lysin. The potential application and mechanism of this CTC method as a general approach to improving drug efficacy, warrants further investigation in the future.
INTRODUCTION
Antibiotics have been used for the treatment of bacterial infection for more than 60 years. Over the past few decades, the extensive use of antibiotics has caused the rapid increase of drug resistance in both Gram-negative and Gram-positive bacteria. There are several life-threatening antibiotics-"ESKAPE" pathogens, which caused the majority of nosocomial infection, including Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species (Rice, 2008) . This situation was headlined as "Bad bugs, No drugs" by The Infectious Diseases Society of America (Boucher et al., 2009) . It is therefore urgent to develop new antibiotics for clinical treatment.
Antimicrobial peptides (AMPs) play an important role in the host defense against pathogenic microbes (Zasloff, 2002; Mansour et al., 2014) . To date, more than 2,500 natural AMPs have been discovered from various species, such as fungi, plants, and animals . One common feature of many AMPs, including melittin, defensin and magainin, is to adopt an amphipathic structure on the membrane of microbes. New derivatives with improved potency have largely been based on the structure-activity relationship, by using these natural AMPs as a reference template (Zelezetsky and Tossi, 2006; Fjell et al., 2012) . Chimeric AMPs, fused from two different AMPs, have also been shown to improve the antimicrobial activity (Fox et al., 2012; Joshi et al., 2012; Ji et al., 2017) . Other successful examples of AMP modification include substitutions with D-form amino acids, β-naphthylalanine, α,α-dialkyl amino acids and peptoids (Taira et al., 2010; Yu et al., 2011; Mojsoska et al., 2015; Chen et al., 2016; Khara et al., 2016) . In summary, AMPs could be the nextgeneration antibiotics to overcome the problem of antibioticresistance (Hancock and Sahl, 2006; Nguyen et al., 2011; Afacan et al., 2012; Omardien et al., 2016; Ageitos et al., 2017) .
We previously identified a novel AMP from human hepatitis B virus core (HBc) protein arginine-rich domain (ARD). This HBcARD peptide exhibited a broad spectrum antimicrobial activity against both Gram-negative and Gram-positive bacteria (Chen et al., 2013) . A. baumannii is one of the most common nosocomial infection worldwide (Dijkshoorn et al., 2007; Kuo et al., 2012) . Colistin and polymyxin B have been considered as the last hope antibiotics against Gram negative bacteria (Cai et al., 2015) . We demonstrated previously that the HBcARD peptide can kill four out of four colistin-resistant A. baumannii in vitro (Chen et al., 2013) . A lung infection mouse model by A. baumannii was established previously (Yang et al., 2016) . It remains to be tested whether HBcARD peptide can show any protection efficacy in the mouse model infected with colistinresistant A. baumannii.
To further improve the potency of our HBcARD AMP, we designed in this study a series of shorter derivative modified from the parental 37-mer HBcARD. By adding a cysteine at the carboxyl terminus (CTC) of a 27-mer peptide D-150-176, we designed a novel peptide D-150-177C, which can protect mice from death, when infected with either Gram-positive S. aureus or Gram-negative A. baumannii. This novel CTC modification strategy was also able to improve the antibacterial activities of other AMPs, such as buforin and lysin. The potential mechanism of efficacy enhancement by the CTC modification warrants further investigation.
MATERIALS AND METHODS

Ethics Statement
This study was carried out in accordance with the recommendations stated in the Guide for the Care and Use of Laboratory Animals, National Research Council, 1996. All animal experiments were conducted under protocols approved by Academia Sinica Institutional Animal Care & Utilization Committee (ASIACUC permit number 12-02-322) and Institutional Animal Care and Use Committee of National Health Research Institutes (NHRI-IACUC-104139).
Bacterial Isolates
The antimicrobial activities of HBcARD peptides were tested using a number of bacterial strains, including Pseudomonas aeruginosa Migula strains (ATCC 27853, and ATCC 9027), Klebsiella pneumoniae strain (ATCC 13884), Escherichia coli strain (ATCC 25922), Staphylococcus aureus strains (ATCC 25923, ATCC 29213, and ATCC 19636) 
Antimicrobial Assay
All peptides were purchased from Yao-Hong Biotechnology Inc. (Taipei, Taiwan). The minimum bactericidal concentration (MBC) was determined as described elsewhere (Chen et al., 2016) . Briefly, bacteria were grown in Mueller-Hinton (MH) broth (Difco) to the mid-logarithmic phase at 37 • C, and were diluted to 10 6 CFU (colony formation unit)/ml in phosphate buffer (10 mM sodium phosphate and 50 mM sodium chloride, pH 7.2). Peptides were diluted in the same buffer. Fifty microliters of bacteria were mixed with 50 µl of serially diluted peptides, followed by incubation at 37 • C for 3 h without shaking. At the end of incubation, bacteria were plated on MH agar. After incubation overnight at 37 • C, the lowest peptide concentration that displayed no bacterial growth (zero colony) was determined as MBC. All peptides were tested in triplicate. For determining the minimum inhibitory concentration (MIC), bacteria were diluted to 10 6 CFU/ml in MH broth. Peptides were also diluted in MH broth. The bacteria (50 µl) were incubated with serially diluted peptides (50 µl) at 37 • C overnight with shaking. Growth of bacteria was measured by the optical density at 600 nm. The lowest peptide concentration, which showed the same OD600 value as the no peptide control, was defined as MIC. All peptides were tested in duplicate.
In Vivo Animal Studies
Specific pathogen free (SPF) mice were housed in the individually ventilated cage (IVC) with light controlled in 12-h day-night periods and temperature controlled at 25 • C. Each cage contains 5 mice. They were given standard laboratory food and water ad libitum. The sample size of animal experiments was estimated by the "resource equation" method (Charan and Kantharia, 2013) .
We determined the in vivo protection efficacy of peptides in two different mouse infection models. In the mouse sepsis model (Chen et al., 2016) , 3-week-old male ICR mice (∼20 g) were purchased from BioLASCO (Taiwan). These mice were inoculated intraperitoneally with S. aureus ATCC 19636 (4 × 10 6 CFU/mouse). At 2 h post-inoculation, the mice were randomly separated into 5 groups and received peptides (5 or 10 mg/kg) or the PBS control, respectively. Each group contained 5 mice. Mortality was monitored daily for 7 days following the bacterial inoculation. This experiment was repeated twice. In the mouse lung infection model (Yang et al., 2016) , 6-8-week-old male C57BL/6JNarl mice (∼27 g) were purchased from National Laboratory Animal Center, Taiwan. The inoculums (3.5 × 10 8 CFU/mouse) were prepared by 1:1 mixing of LB culture and 10% mucin (Sigma). All mice were randomly separated into 3 groups and anesthetized by Isoflurane via inhalation, and inoculated intra-tracheally with colistin-resistant A. baumannii TCGH 46709. Two hours after inoculation, the mice were intraperitoneally injected daily with either colistin (5 mg/kg) (Fishbain and Peleg, 2010) or HBcARD derivative peptides (5 or 10 mg/kg), respectively, for three consecutive days. Each group contained 8 mice. Mortality was monitored every 12 h following the bacterial inoculation. This experiment was repeated twice.
To measure in vivo the acute toxicity, 3-week-old male ICR mice (∼20 g) were purchased from BioLASCO (Taiwan). The mice were randomly separated into 6 groups, and were intraperitoneally injected with D-150-177C at concentrations of 20, 40, 60, and 80 mg/kg. A last-line antibiotic, polymyxin B (20 and 50 mg/kg), was used as a control. Each group contained 5 mice. At 1 day post-injection, blood sample was collected from each mouse. The liver function of mice was determined by measuring the ALT level in the blood. The survival rates of injected mice were monitored for 7 days.
Statistical Analysis
Statistical analysis was performed using the Graphpad software. Survival curves of all groups were plotted by the Kaplan-Meier method and analyzed by the log-rank test.
RESULTS
The Importance of the Terminal Cysteine
In our previous results (Chen et al., 2013) , we found that the antimicrobial activity against S. aureus was diminished, when the HBcARD peptide lost the last 8 amino acids (SQSRESQC). To further improve the potency of our lead compound HBcARD, we tested the antimicrobial activity of several HBcARD derivatives, including peptides modified by truncation and D-arginine substitution for L-arginine (Figure 1) . The antimicrobial activities of these peptides were determined by minimal bactericidal concentration (MBC). Like the parental peptide HBcARD 147-175 (Chen et al., 2013) , the derivative peptides HBcARD 150-176S and HBcARD 150-177Q showed no detectable bactericidal activity against S. aureus (Table 1) . To mimic the parental peptide HBcARD 147-183 with a cysteine at the carboxyl terminus, we designed another derivative HBcARD 150-177C, by replacing the terminal Q (glutamine) residue of HBcARD 150-177Q with a C (cysteine) residue (Figure 1) . The results showed that this Q-to-C substitution effectively rescued the bactericidal activity against three S. aureus. In addition, HBcARD 150-177C also retained the same spectrum and potency of antimicrobial activity against a number of Gram-negative bacteria ( Table 1) . We asked next whether the length of HBcARD 150-177C peptide (28-mer) can be further reduced. The potency against S. aureus ATCC19636 was no longer detectable up to 57.2 mg/L for peptides 150-171C (20-mer), 157-177C (21-mer), and 164-177C (14-mer). Altogether, these results here indicated that both arginine and C-terminal cysteine are important for antibacterial activity.
Protection Efficacy of Modified HBcARD in Two Animal Models
As shown in Figure 2A , we compared the in vivo protection efficacies between HBcARD 150-177Q and 150-177C peptides in the ICR mouse sepsis model. The mice (∼20 g) were i.p. (intraperitoneally) inoculated with S. aureus ATCC19636 (4 × 10 6 CFU/mouse), followed by treatments with peptides or the PBS control at 2 h post-inoculation. We monitored the survival rate for 7 days ( Figure 2B ). All mice treated with PBS (10/10) died at day 1 post-inoculation. Consistent with its low in vitro MBC against S. aureus, administration of L-150-177Q peptide at the dose of 10 mg/kg showed a very low protection efficacy (2/10 survival). In contrast, administration of L-150-177C peptide at the same dose protected 70% of mice (7/10) from death (p < 0.05). It appears that the C-terminal cysteine is very critical for the in vivo protection as well. Next, we compared the in vivo protection efficacy of HBcARD 150-177C peptides containing either Dform or L-form arginines in this same model. The protection efficacy of peptide L-150-177C was 30% (3/10) at 5 mg/kg, whereas D-150-177C can protect all mice (10/10) from death at the same dose ( Figure 2B) . The results indicated that D-150-177C had a stronger protection effect than L-150-177C (p < 0.01).
In addition to the Gram-positive S. aureus, we performed another mouse lung infection model to investigate the protection of D-150-177C peptide against the Gram-negative A. baumannii ( Figure 2C ). C57BL/6JNarl mice (∼27 g) were anesthetized and intra-tracheally inoculated with A. baumannii (3.5 × 10 8 CFU/mouse). At 2 h post-inoculation, the mice received i.p. injection of either D-150-177C or colistin, respectively, for three consecutive days (1 injection per day). In one experiment with colistin-sensitive A. baumannii ATCC17978 strain, the administration of D-150-177C resulted in a survival rate comparable to that of colistin treatment (data not shown). In the other experiments infected with colistin-resistant A. baumannii TCGH 46709 strain, 12.5% mice (2/16) were poorly rescued by colistin (5 mg/kg/day). In contrast, peptide D-150-177C at the dose of 5 and 10 mg/kg/day protected 62.5% (10/16, p < 0.01) and 87.5% (14/16, p < 0.001) of mice from death, respectively ( Figure 2D) . These results indicated that D-150-177C exhibited a better protection efficacy than colistin for the colistin-resistant A. baumannii.
Peptide D-150-177C Showed Very Low in Vivo Toxicity Than Polymyxin B
Polymyxins are the last-line antibiotics, but could be toxic at higher dose. We compared the acute toxicity of peptide D-150-177C with polymyxin B using ICR mice. The mice (∼20 g) were i.p. injected with D-150-177C peptide (20-80 mg/kg body weight). Polymyxin B (50 mg/kg body weight) was used as a control antibiotic. As shown in Figure 3A , all mice treated with peptide D-150-177C at the dose of 20 and 40 mg/kg survived; while at 60 and 80 mg/kg, the survival rates dropped from 100 to 80% (4/5) and 40% (2/5). The LD 50 of D-150-177C peptide was 
ND, not detectable at the concentration up to 57.2 mg/L; -, not determined.
estimated to be 75 mg/kg. In contrast, all mice died of polymyxin B at 50 mg/kg. Therefore, the acute toxicity of peptide D-150-177C is significantly lower than polymyx B. On the other hand, we also monitored liver injury by measuring serum ALT levels in blood samples from mice at 1 day post-injection. At the dose of 60 mg/kg, D-150-177C peptide showed slightly elevated level of ALT compared to mice treated with 20 mg/kg polymyxin B ( Figure 3B ).
Antimicrobial Activity of Peptide D-150-177C Against Clinical Isolates
We determined the antimicrobial activity of peptide D-150-177C against 20 clinical isolates obtained from TSAR (Taiwan Surveillance of Antimicrobial Resistance), including E. coli, K. pneumoniae, A. baumannii, and P. aeruginosa. As shown in Table 2 , 19 out of 20 isolates were drug-resistant to various antibiotics. Despite their diverse drug-resistant phenotypes, they There was a dose-dependent effect on the survival rate of mice receiving D-150-177C. The survival rates of mice treated with D-150-177C were significantly higher than that with colistin treatment. This result indicated that D-150-177C was more potent than colistin for killing colistin-resistant A. baumannii. * P < 0.05; * * P < 0.01; * * * P < 0.001.
were invariably inhibited by the peptide D150-177C at the range of 16 to 32 mg/L except for K. pneumoniae.
Comparison of in Vivo Protection Efficacies Among Various Modified 150-177C Peptides
Peptide D-150-177C contains a total of 14 L-arginines substituted with 14 D-arginines (Figure 1 ). This modified peptide showed increased antimicrobial activity (Figure 2) . Because D-arginine is far more expensive than L-arginine, we investigated the possibility of partial D-arginine substitution in the mouse sepsis model. The in vivo protection efficacies were compared between peptides containing complete or partial D-arginine substitutions. We designed two partial D-arginine-substituted peptides, designated as DL-and LD-150-177C (Figure 1) . Both peptide DL-150-177C and all-D-arginine peptide D-150-177C protected all mice from death (Figure 4) . While peptide LD-150-177C appeared to be less protective (80% survival rate), but there were no significant difference between these two (P > 0.05).
Enhancement of Antimicrobial Activity via a C-terminal Cysteine (CTC)
To determine whether the CTC modification strategy can be applied to enhance the spectrum and efficacy of other AMPs, we compared the antibacterial activities between AMPs with and without the CTC modification. We chose buforinII (Park et al., 1998) and lysin (Thandar et al., 2016) , whose amino acid sequences bear no resemblance to HBcARD (Figure 1) . As shown in Table 3 , buforinIIC exhibited fourfold enhancement over buforinII in the antimicrobial activity against P. aeruginosa. This modification also enhanced the antimicrobial activity against both K. pneumoniae and A. baumannii, albeit it showed no effect against S. aureus at the concentration up to 1024 mg/L. Similar enhancement of antimicrobial activity by CTC modification was observed in another AMP lysin. Remarkably, the MBC against P. aeruginosa, K. pneumoniae, A. baumannii, and S. aureus were all significantly enhanced. For example, compared to its parental lysin without a C-terminal cysteine, LysinC exhibited a 4-fold, >8-fold, >8-fold, and 32-fold decrease in MBC against P. aeruginosa, K. pneumonia, S. aureus, and A. baumannii, respectively.
DISCUSSION
Hydrophobic residues in the amphipathic structure of AMPs are known to play an important role in the structure-activity studies (Fjell et al., 2012) . However, in this study, we observed similar antimicrobial activity of HBcARD after deleting three hydrophobic residues (TVV) from the N-terminus (Figure 1 and Table 1 ). It suggests that these hydrophobic residues at the N-terminus were not required for the antimicrobial activity. At the C-terminus of HBcARD147-183, the last 8 amino acids (SQSRESQC) appeared to be critical for the potency against S. aureus (Chen et al., 2013) . It is unclear how these terminal residues could affect the potency. We tested the hypothesis whether the terminal cysteine residue in peptide 150-177C could contribute to the bactericidal activity, by comparing peptides 150-176S, 150-177Q, and 150-177C (Figure 1) . Only 150-177C exhibited marked in vitro and in vivo activity against S. aureus (Table 1 and Figure 2B) . Therefore, the C-terminal cysteine residue (CTC) can enhance the antimicrobial activity of HBcARD peptide against S. aureus. In addition to the C-terminal cysteine, the arginine content appeared to be important as well, based on the deletion mapping experiment (peptides 150-171C, 157-177C, and 164-177C). In summary, a C-terminal cysteine and a sufficient number of arginine are important for the HBcARD peptide.
In our previous studies, we successfully improved the in vivo potency of the prototype 37-mer HBcARD by D-arginine substitution in a mouse sepsis model (Chen et al., 2016) . Using this same strategy, we demonstrated here that a 28-mer peptide 150-177C significantly improved the protection efficacy from 30% by the L-150-177C to 100% by D-150-177C at the dose of 5 mg/kg ( Figure 2B) . So far, our most active derivative is the 28-mer D-150-177C peptide. To reduce the cost for D-amino acids in peptide synthesis, we engineered peptides DL-150-177C and LD-150-177C, which contain only approximately 50% of D-arginine substitution. These partially D-substituted peptides displayed bactericidal activity similar to peptide D-150-177C, which contains 100% of D-arginines. It is possible that the protection efficacy can be maintained or improved by further reduction in the number of D-amino acid replacement in the future. Moreover, in our current assay, we measured only the survival rate as the end point. It is worth mentioning here that in our previous studies, bacterial burdens in spleen, liver, and blood were reduced by approximately 100-fold in all tissues in mice treated with full-length HBcARD (Chen et al., 2013) .
Drug-resistance bacteria not only can cause therapeutic complications, but also increase the economic burden in hospitals (Perencevich et al., 2003) . Therefore, we determined the antimicrobial activity of D-150-177C against 19 clinical isolates with a wide spectrum of drug resistance profiles ( Table 2) . Except for most strains of K. pneumonia, peptide D-150-177C, in the concentration between 16 and 32 mg/L, inhibited these drugresistant E. coli, A. baumannii, and P. aeruginosa. Because the MIC values between drug-sensitive and drug-resistant strains are similar ( Table 2 and data not shown), we observed no crossresistance in vitro from these clinical isolates to D-150-177C.
Polymyxin B and colistin (polymyxin E) are the "lastline" antibiotic peptides currently used in clinical medicine for treatment of drug-resistant Gram-negative bacteria (Cai et al., 2015) . However, many cases of colistin-and polymyxin B-resistant strains are emerging, worldwide (Fernandez et al., 2010; Cai et al., 2012; Baadani et al., 2013; Lesho et al., 2013; Lopez-Rojas et al., 2013) . A. baumannii is one of the most common antibiotic-resistant pathogens globally, which can cause a wide variety of infections in lung, bloodstream, urinary tract and surgical wounds (Dijkshoorn et al., 2007; Kuo et al., 2012) . In our mouse model i.t. infected with colistin-resistant A. baumannii, treatment with D-150-177C can protect 90% of mice from death ( Figure 2D) . The lack of cross-resistance in vivo suggested that colistin and D-150-177C must have different modes of action.
A high rate of nephrotoxicity is known to be associated with polymyxins (Doshi et al., 2011; Abdelraouf et al., 2012; Omrani et al., 2015; Roberts et al., 2015) . In our acute toxicity mouse model, 80% of mice receiving 60 mg/kg peptide D-150-177C survived, while 100% of mice died of polymyxin B at 50 mg/kg ( Figure 3A) . Although the mice receiving peptide D-150-177C (60 mg/kg) had an elevated ALT level compared to polymyxin B (20 mg/kg) treated mice (Figure 3B) , the average ALT value appeared to fall in the range of the basal level (less than 100 IU/L) of untreated mice (see Materials and Methods). Taken together, treatment with D-150-177C peptide appeared to be well tolerated in the mouse model. Finally, in our current study, we performed no accumulative toxicity assays. This is because in our current short-term study, we tested only one-shot treatment for the sepsis model, and only three shots in 3 days for the lung infection model (Figure 2) .
Ionic strength in the medium has been shown to influence the antibacterial activities of human beta-defensin 3 (hBD-3) derivatives (Boniotto et al., 2003; Kluver et al., 2005) . In addition, it has been reported that polyanionic peptides present in LB and BHI media may form electrostatic complexes with cationic polymers, which would decrease the potency by diminishing the binding to the anionic lipopolysaccharide layer of E. coli. (Choi et al., 2014) . In our studies, we noted that the MIC values were not always in parallel with the MBC values. For example, the MICs ) . Altogether, it is important to include an in vivo assay in an animal model, when the antibacterial activity is being evaluated, as the in vitro MIC assay could be subject to the influence of ionic strength in the broth. Previously, we demonstrated that the C-terminal octamer peptide SQSRESQC of HBcARD is important for the antibacterial activity against S. aureus (Chen et al., 2013) . This observation was confirmed recently. When phage lysin was conjugated with FIGURE 4 | In vivo protection efficacy of partially modified 150-177C peptides in a mouse sepsis model. Two hours post-inoculation, the mice (n = 10/group) were treated with 5 mg/kg of HBcARD peptides modified with 50 and 100% D-arginine substitutions (D-150-177C, DL-150-177C, and LD-150-177C in Figure 1 ). All of these peptides can successfully protect S. aureus-infected mice from death with a high efficiency (80 -100%).
this octamer peptide of HBcARD or a scrambled peptide, the antibacterial activity of phage lysin was enhanced (Thandar et al., 2016) . The principal determinant for this activity enhancement has remained ill-defined. In our investigation on the modification of HBcARD, we invented a CTC modification strategy (Table 3) . In this approach, antibacterial activity or spectrum, including Gram-positive and Gram-negative, can be improved by adding an exogenous cysteine to the end of the C-terminus of an AMP, regardless of its sequence context. We cited here two such successful examples using the less potent buforinII and lysin. On the other hand, we experienced unsuccessful examples via CTC modifications, such as indolicidin, magainine and epinecidin-1 (data not shown).
It remains unclear what could be the mechanism for the CTC-mediated enhancement. It is unlikely that the effect is simply due to the peptide dimerization via the cysteine disulfide bond formation. The CTC enhancement effects are variable, depending on the bacteria being treated; however, the increased antibacterial activities are in general far greater than twofold. To date, a rich AMP database includes near three thousand naturally occurring AMPs . It should be rewarding to explore systematically, whether this simple CTC modification approach could help broaden the spectrum and boost the activity of these AMPs against various drug-resistant microorganisms in clinical medicine.
